This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Acasti Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$31.26m
Eşitlik	US$96.72m
Toplam yükümlülükler	US$20.08m
Toplam varlıklar	US$116.80m

Son finansal sağlık güncellemeleri

Recent updates

Acasti Pharma (CVE:ACST) Is In A Good Position To Deliver On Growth Plans

Mar 01

Acasti Pharma (CVE:ACST) Is In A Strong Position To Grow Its Business

Aug 17

Is Acasti Pharma (CVE:ACST) In A Good Position To Invest In Growth?

Jan 12

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ACST's short term assets ($33.4M) exceed its short term liabilities ($3.4M).

Uzun Vadeli Yükümlülükler: ACST's short term assets ($33.4M) exceed its long term liabilities ($16.6M).

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ACST is debt free.

Borcun Azaltılması: ACST has no debt compared to 5 years ago when its debt to equity ratio was 13.6%.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: ACST has sufficient cash runway for more than a year based on its current free cash flow.

Tahmini Nakit Akışı: Insufficient data to determine if ACST has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

This company listing is no longer active

Acasti Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Acasti Pharma (CVE:ACST) Is In A Good Position To Deliver On Growth Plans

Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule

Acasti Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Acasti Pharma (CVE:ACST) Is In A Strong Position To Grow Its Business

Acasti Intends to Request Hearing Before Nasdaq Panel to Present Plan of Compliance

Is Acasti Pharma (CVE:ACST) In A Good Position To Invest In Growth?

Recent updates

Acasti Pharma (CVE:ACST) Is In A Good Position To Deliver On Growth Plans

Acasti Pharma Inc. to Report Q3, 2023 Results on Feb 14, 2023

Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule

Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia

Acasti Pharma Inc. Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)

High number of new and inexperienced directors

Acasti Pharma Inc. to Report Q2, 2023 Results on Nov 14, 2022

Acasti Pharma Inc. Announces Board Changes

Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, Drug Candidate for the Treatment of Ataxia Telangiectasia

Acasti Pharma Inc. to Report Q1, 2023 Results on Aug 11, 2022

Acasti Pharma Inc., Annual General Meeting, Sep 28, 2022

Acasti Pharma Inc. Announces Initiation of Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia

No longer forecast to breakeven

Acasti Pharma Announces the Issuance of Additional Patents for GTX-104 and GTX-101

Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting All Endpoints

Less than half of directors are independent

Less than half of directors are independent

Acasti Pharma Inc. Announces Interim Data Meets All Primary Endpoints for Pivotal PK Study for GTX-104

Acasti Pharma Inc. Announces Initiation of Pharmacokinetic Bridging Study for GTX-104, its Lead Drug Candidate for Treatment of Subarachnoid Hemorrhage

Acasti Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Acasti Pharma Inc. (TSXV:ACST) completed the acquisition of Grace Therapeutics, Inc.

Acasti Pharma (CVE:ACST) Is In A Strong Position To Grow Its Business

Forecast breakeven pushed back to 2024

Acasti Intends to Request Hearing Before Nasdaq Panel to Present Plan of Compliance

Acasti Pharma Inc. (TSXV:ACST) entered into a definitive agreement to acquire Grace Therapeutics, Inc. for $71.4 million.

Investor sentiment deteriorated over the past week

Earnings miss expectations

New 90-day high: CA$1.13

Is Acasti Pharma (CVE:ACST) In A Good Position To Invest In Growth?

New 90-day high: CA$0.72

New 90-day high: CA$0.55

New 90-day high: CA$0.47

Acasti Pharma Inc. Announces Resignation of Brian Groch as Chief Commercial Officer, Effective December 31, 2020

New 90-day low: CA$0.24

Acasti Pharma Inc. Announces Executive Changes

New 90-day low - CA$0.32

Acasti Pharma Inc. Auditor Raises 'Going Concern' Doubt

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin